Evolent Q2 revenue $647M (+38% YoY); net loss narrows to $6.4M; Adj. EBITDA $52M; narrows FY outlook

Evolent Health, Inc.

2024-Q2 EPS reported -$0.28 revenue$1,286,798,000

Revenue $647.1M, up 37.9% YoY from $469.1M; net loss $(6.4)M vs $(41.4)M loss in Q2 2023.
Adjusted EBITDA $52.0M (8.0% margin) vs $47.4M (10.1% margin) in prior year.
Narrows full-year 2024 revenue outlook and updates Adjusted EBITDA guidance; reaffirms $300M exit run rate target.
Performance Suite average lives grew to 6,901 from 3,810 YoY; signed new oncology and specialty deals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.